Bank of America Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $304.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price decreased by Bank of America from $306.00 to $304.00 in a research note issued to investors on Monday morning, MarketBeat.com reports. Bank of America currently has a buy rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on ASND. Citigroup initiated coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They set a “buy” rating and a $355.00 target price on the stock. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. BMO Capital Markets started coverage on Ascendis Pharma A/S in a research report on Tuesday, August 18th. They set an “outperform” rating and a $319.00 price target on the stock. Evercore restated an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Finally, Weiss Ratings raised Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $310.05.

Ascendis Pharma A/S Trading Up 2.7%

Shares of ASND opened at $267.31 on Monday. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The firm’s 50-day moving average price is $257.46 and its 200-day moving average price is $240.09. The firm has a market capitalization of $16.67 billion, a price-to-earnings ratio of 20.74 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post 6.08 EPS for the current year.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was acquired at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This trade represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 40.00% of the company’s stock.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently made changes to their positions in the stock. Advisory Services Network LLC purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $26,000. Arax Advisory Partners raised its stake in Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 104 shares during the last quarter. Leonteq Securities AG purchased a new position in Ascendis Pharma A/S during the fourth quarter valued at $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S in the fourth quarter worth $42,000. Finally, Global Retirement Partners LLC boosted its holdings in Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares in the last quarter.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Oppenheimer raised its price target to $312 from $304 while maintaining an “Outperform” rating, indicating increased confidence in Ascendis Pharma’s outlook. Oppenheimer Adjusts Price Target on Ascendis Pharma
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $345 price target while dramatically increasing its FY2026 earnings-per-share forecast to $17.04 from $3.93. The upgrade provides a significant bullish earnings catalyst, although it contrasts with the firm’s lower estimates for later periods.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating and set a $327 price target, suggesting substantial potential upside from the reference price. Wedbush Reaffirms Ascendis Pharma Outperform Rating
• Positive Sentiment: Ascendis Pharma received an average analyst rating of “Buy,” reinforcing broadly favorable Wall Street sentiment. Ascendis Pharma Receives Average Buy Rating
• Neutral Sentiment: HC Wainwright lowered its FY2027 EPS forecast to $11.25 from $11.88 and reduced estimates for several 2026–2027 quarters. However, the firm retained its Buy rating and $345 target, suggesting the revisions may reflect timing or modeling changes rather than a change in its overall investment thesis.
• Negative Sentiment: Bank of America lowered its price target to $304, creating a modest counterpoint to the positive revisions from Oppenheimer, Wedbush and HC Wainwright. Bank of America Lowers Ascendis Pharma Price Target

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.